Anti-Mouse/Human CD44 (Clone IM7) – PE

Anti-Mouse/Human CD44 (Clone IM7) – PE

Product No.: C254

[product_table name="All Top" skus="C254"]

- -
- -
Clone
IM7
Target
CD44
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Pgp-1, Ly-24, H-CAM
Isotype
IgG2b
Applications
FC

- -
- -
Select Product Size

Data

- -
- -

Antibody Details

Product Details

Reactive Species
Human
Mouse
Host Species
Rat
Product Concentration
0.2 mg/ml
Formulation
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This R-PE conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Shipping
Next Day 2-8°C
Excitation Laser
Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone IM7 recognizes an epitope common to alloantigens and all isoforms of CD44 that is located between amino acids 145 and 186.
Background
CD44 is an 80-95 kD glycoprotein that plays a role in various cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. CD44 interacts with osteopontin, collagens, and matrix metalloproteinases (MMPs) and is a receptor for hyaluronic acid. Transcripts for this gene go through intricate alternative splicing that result in a variety of functionally distinct isoforms, including those which may be related to tumor metastasis. These splice variants of CD44 function as receptors under hemodynamic flow conditions that are significant to the development of cancer metastasis. Hence, it is thought that anti-CD44 tumor-specific mAbs may have therapeutic potential. This therapeutic potential of anti-CD44 mAbs is evident in some animal experiments demonstrating a reduction in malignant activities of various neoplasms when CD44 was targeted by a combination of mAbs, antisense oligonucleotides, and CD44-soluble proteins. It has been reported that high levels of CD44 on leukemic cells fuel leukemia production. Notably, various cancer studies show conflicting results pertaining to level of CD44 expression and its correlation with disease prognosis. Before anti-CD44 therapy can be applied to human cancers, it is essential to resolve this inconsistency.
Antigen Distribution
CD44 is expressed on all leukocytes, endothelial cells, hepatocytes, and mesenchymal cells in addition to B-cells, monocytes, macrophages and certain subsets of thymocytes and peripheral T-cells. Mice with the Ly-24.1 allotype have high densities of CD44+ T-cells.

Antigen Details

Ligand/Receptor
Hyaluronan, MIP-1β, fibronectin, collagen
PubMed
NCBI Gene Bank ID
Research Area
Cell Adhesion
.
Cell Biology
.
Immunology
.
Stem Cell

References & Citations

1. Trowbridge, I. et al. (1982) Immunogenetics 15:299 2. Lesley, J. et al. (1988) Cell Immunol. 112:40
Flow Cytometry

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.